Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-1
2023-509053-32-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Durvalumab + TACE, Durvalumab + bevacizumab + TACE and Placebo + TACE (3 arms). Primary endpoint: Progression-free survival (PFS). Started Feb 2024; status: completed.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-509053-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509053-32-00.